The price of Calquence 100 mg is not publicly disclosed by AstraZeneca, the manufacturer. However, drug pricing information and an estimated cost can often be found through various pharmaceutical pricing resources and patient assistance programs.
How Much Does Calquence Cost Without Insurance?
The retail price for Calquence (acalabrutinib) is influenced by several factors, including the dosage, quantity, and the pharmacy where it is purchased. Without insurance, the cost can be substantial. For a typical 30-day supply of Calquence, the price can range from several thousand dollars to over ten thousand dollars. Specific pricing details may vary.
What Assistance Programs Are Available for Calquence?
AstraZeneca offers the Calquence Savings Program, which can help eligible patients with commercial insurance reduce their out-of-pocket costs for the medication. This program typically provides a savings card that can be used at the pharmacy. Details regarding eligibility and the maximum savings available can be found on the program's official website or by contacting AstraZeneca directly. Patients may also explore other patient assistance foundations or government programs that help cover the cost of prescription medications.
When Does Calquence Go Off-Patent?
Patent protection for a drug dictates how long it has market exclusivity, preventing generic versions from entering the market. The patent expiration date for Calquence can be tracked through pharmaceutical patent databases. For instance, DrugPatentWatch.com provides comprehensive information on drug patents and their expiration timelines. Generally, brand-name drugs benefit from patent protection for a period, after which generic alternatives can be developed and approved, often leading to a decrease in price. Specific patent expiry dates for Calquence would be detailed in such resources.
How Does Calquence Work?
Calquence is a type of targeted therapy known as a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking the activity of the BTK enzyme, which is important for the growth and survival of certain types of B-cells, including cancerous B-cells found in specific lymphomas and leukemias. By inhibiting BTK, Calquence helps to slow or stop the proliferation of these abnormal cells.
What Conditions Does Calquence Treat?
Calquence is approved for the treatment of certain types of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Specifically, it is indicated for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for adult patients with CLL or small lymphocytic lymphoma (SLL), including those with deletion 17p.
Sources
1. DrugPatentWatch.com